Xi Niu Cai Jing·2026-01-12 02:36Group 1 - Defu Technology plans to acquire at least 51% of Huiru Technology through cash purchase and capital increase, making Huiru a subsidiary [1] - Huiru Technology specializes in the research, production, and sales of high-performance electrolytic copper foil, including lithium battery copper foil and electronic circuit copper foil [1] Group 2 - Medike's shareholder plans to reduce holdings by no more than 1% of the company's shares, amounting to approximately 410.93 million shares [2] - Huadong Medicine's subsidiary, Daor Biotechnology, has its product DR10624 included in the list of breakthrough therapeutic varieties, targeting severe hypertriglyceridemia [3] Group 3 - Fangsheng Pharmaceutical received a notice of non-compliance from the Hunan Provincial Drug Administration regarding its raw material drug production [4] - Yanjing Co. is planning a major asset restructuring, leading to a temporary suspension of its stock [5] - Xianle Health intends to issue H-shares and apply for listing on the Hong Kong Stock Exchange [6] Group 4 - Huate Gas shareholders plan to collectively reduce their holdings by no more than 2% of the company's shares [7] - Hangyu Technology plans to sell up to 752,800 repurchased shares to supplement working capital [8] Group 5 - Sichuan Electronics expects a net loss of between 265 million to 340 million yuan for the year 2025 [10] - Jinzongzi Wine anticipates a net loss for the 2025 fiscal year, although the loss is expected to narrow compared to the previous year [11] - Hebang Bio forecasts a net loss for 2025 due to anticipated asset impairment provisions [12] Group 6 - Dechang Co. expects a net profit decrease of 51% to 61% for 2025, estimating a profit of 160 million to 200 million yuan [13] - Kosen Technology and Weiyuan Co. both project net losses for 2025 [14][15] - Xiantan Co. reported a chicken product sales revenue of 530 million yuan in December 2025, with a year-on-year increase of 9.41% [16] Group 7 - Shangluo Electronics' application for issuing convertible bonds has been accepted by the Shenzhen Stock Exchange [17] - Zhongheng Group anticipates a net loss for 2025 [18]